New clinical trials policy at FDA

被引：14

|

作者：

Vastag, Brian

机构：

来源：

NATURE BIOTECHNOLOGY | 2006年 / 24卷 / 09期

关键词：

D O I：

10.1038/nbt0906-1043

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

收藏

页码：1043 / 1043

页数：1

相关论文

共 50 条

[41] THE PLACEBO CONTROL IN CLINICAL-TRIALS (A VIEW FROM THE FDA)
LEBER, P
PSYCHOPHARMACOLOGY BULLETIN, 1986, 22 (01) : 30 - 32
[42] FDA SEEKS MORE DATA ON WOMEN IN CLINICAL-TRIALS
BARNETT, AA
LANCET, 1995, 346 (8986): : 1357 - 1357
[43] Requirements for contraception use in clinical drug trials submitted to FDA
Uhl, K
Pinnow, E
Scott, P
Derbis, J
Toigo, T
JOURNAL OF WOMENS HEALTH, 2006, 15 (04) : 472 - 472
[44] FDA oversight of clinical trials is "grossly inadequate," say experts
Demasi, Maryanne
BMJ-BRITISH MEDICAL JOURNAL, 2022, 379
[45] Policy and regulations Streamlining clinical trials
Burke, Maria
CHEMISTRY & INDUSTRY, 2013, 77 (04) : 7 - 7
[46] US FDA requests hold on early clinical trials of atezolizumab
Reactions Weekly, 2017, 1671 (1) : 6 - 6
[47] FDA Perspective: Enrolment of Elderly Transplant Recipients in Clinical Trials
Meyer, Joette M.
Archdeacon, Patrick
Albrecht, Renata
TRANSPLANTATION, 2013, 95 (07) : 916 - 918
[48] Stem cells and the FDA: Regulatory considerations for proceeding to clinical trials
Fink, Donald W., Jr.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2005, 41 : 7A - 7A
[49] FDA oversight of clinical trials is "grossly inadequate," say experts
Demasi, Maryanne
BMJ-BRITISH MEDICAL JOURNAL, 2022, 379
[50] Clinical medicine - FDA to release data on gene therapy trials
Kaiser, J
SCIENCE, 2001, 291 (5504) : 572 - 573

← 1 2 3 4 5 →